Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 801–900 of 1,006
He, J.-J., Ouyang, W., Zhao, W., Shao, L., Li, B., Liu, B., Wang, D., Han‐Zhang, H., Zhang, Z., Shao, L., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7553 · Cited by 40
“Biomarkers, such as the expression of programmed deathligand 1 (PD-L1), high microsatellite instability (MSI-H), and tumor mutational burden (TMB) have shown promising value for predicting the prognosis of ICI-treated patients and have been explored extensively (6-9).”
BackgroundRational nanocarrier design towards clinical translation of cancer nanotherapy
Guo, D., Ji, X., & Luo, J. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe35a · Cited by 40
Song, Q., Zhang, G., Wang, B., Cao, G., Li, D., Wang, Y., Zhang, Y., Geng, J., Li, H., & Li, Y. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c08201 · Cited by 42
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
Boutros, A., Cecchi, F., Tanda, E. T., Croce, E., Gili, R., Arecco, L., Spagnolo, F., & Queirolo, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.733917 · Cited by 40
“Indeed, several studies observed that CSCC is the tumor with the highest TMB (7), with a linear relationship between tumor mutational burden and immunotherapy efficacy (37).”
BackgroundWu, M. J., Liu, J., Wu, S., Liu, J., Wu, H., Yu, J., & Meng, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803247 · Cited by 45
Chuckran, C. A., Cillo, A. R., Moskovitz, J. M., Overacre-Delgoffe, A. E., Somasundaram, A., Shan, F., Magnon, G. C., Kunning, S. R., Abécassis, I., Zureikat, A. H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf8495 · Cited by 41
“This paradigm has held true across numerous solid tumor types, from melanoma (Mel) to hepatocellular carcinoma, with varying response rates (2).”
BackgroundBiomarkers for predicting the efficacy of immune checkpoint inhibitors
Wang, C., Wang, H.-N., & Wang, L. (2022) · Journal of Cancer · doi:10.7150/jca.65012 · Cited by 44
“A statistic correlation between TMB and response rate to anti-PD-1 therapy was observed across different types of tumor [43,44].”
BackgroundZeng, C., Liu, Y., He, R. X., Lu, X., Dai, Y., Qi, G., Liu, J., Deng, J., Lu, W., Jin, J., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.935056 · Cited by 43
“However, response rates of immune checkpoint inhibitors remain low (Yarchoan et al., 2017).”
BackgroundJammihal, T., Saliby, R. M., Labaki, C., Soulati, H., Gallegos, J., Peris, A., McCurry, D., Yu, C., Shah, V., Poduval, D., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00896-w · Cited by 38
“The common paradigm in solid tumor immunology is that a higher tumor mutational burden (TMB) positively predicts outcomes to immunotherapy 5–7 .”
Guo, Y., Xie, F., Liu, X., Ke, S., Chen, J., Zhao, Y., Li, N., Wang, Z., Yi, G., Shen, Y., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad067 · Cited by 44
Predictive biomarkers for immunotherapy response in extensive-stage SCLC
Zhu, L., & Qin, J. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05544-x · Cited by 40
“TMB is a biomarker for the outcome of immunotherapy in various tumor types, including lung cancer (Hellmann et al. 2018a; Yarchoan et al. 2017), but the use of TMB to predict the efficacy of immunotherapy for SCLC is still controversial, and the results of different studies are inconsistent (Sholl…”
ResultCombining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
van de Haar, J., Mankor, J. M., Hummelink, K., Monkhorst, K., Smit, E. F., Wessels, L. F. A., Cuppen, E. P. J. G., Aerts, J. G. J. V., & Voest, E. E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4027 · Cited by 51
Reference Materials for Improving Reliability of Multiomics Profiling
Ren, L., Shi, L. M., & Zheng, Y. (2024) · Phenomics · doi:10.1007/s43657-023-00153-7 · Cited by 40
Lymphatic system regulation of anti-cancer immunity and metastasis
Lei, P., Fraser, C. S., Jones, D., Ubellacker, J. M., & Padera, T. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1449291 · Cited by 45
Xu, S., Chen, X., Ying, H., Chen, J., Ye, M., Lin, Z., Zhang, X., Shen, T., Li, Z., Zheng, Y., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12911-5 · Cited by 40
“Multiple studies have indicated a correlation between TMB and the response rate to ICB therapy in various tumor types [48, 49].”
BackgroundDeficient Mismatch Repair and Microsatellite Instability in Solid Tumors
Awosika, J. A., Gulley, J. L., & Pastor, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094394 · Cited by 42
“As a result, the existence of the hypermutated phenotype exhibited by dMMR/MSI-H tumors further supports the likelihood of an efficacious response to ICI and favorable outcome [128,131,132].”
Immunotherapy strategy of EGFR mutant lung cancer.
Yu, S., Liu, D., Shen, B., Shi, M., & Feng, J. (2018) · Europe PMC (PubMed Central) · Cited by 42
Siah, K. W., Khozin, S., Wong, C. H., & Lo, A. W. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00046 · Cited by 41
“In fact, there is emerging evidence that variables such as tumor-mutational burden are predictive of response to immunotherapy.(23) We believe the same also applies, albeit to a lesser extent, to EGFR and ALK TKIs because not all patients with EGFR- and ALK-positive disease responded to treatment.”
BackgroundJiao, X., He, X., Qin, B., Liu, K., Wu, Y., Liu, J., Hou, T., & Zang, Y. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.11.04 · Cited by 43
“The definition of TMB is the total number of mutations per coding area of a tumor genome (28).”
BackgroundNanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers
Acebes-Fernández, V., Landeira‐Viñuela, A., Juanes‐Velasco, P., Hernández, Á., Otazo‐Pérez, A., Manzano-Román, R., Góngora, R., & Fuentes, M. (2020) · Nanomaterials · doi:10.3390/nano10071274 · Cited by 43
“For some tumours, this parameter may be a suitable clinical biomarker for making immunotherapy treatment decisions [324,325].”
BackgroundBenchmarking HLA genotyping and clarifying HLA impact on survival in tumor immunotherapy
Li, X., Zhou, C., Chen, K., Huang, B., Liu, Q., & Ye, H. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12895 · Cited by 40
Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
Eltahir, M., Isaksson, J., Mattsson, J. S. M., Kärre, K., Botling, J., Lord, M., Mangsbo, S. M., & Micke, P. (2021) · Cancers · doi:10.3390/cancers13133116 · Cited by 39
“As an alternative, the tumor mutation burden (TMB), the number of mutations present in the tumor per coding area, has been suggested as a better biomarker for predicting anti-PD-(L)1 therapy outcomes across many cancers, including NSCLC [13,14].”
BackgroundChui, N. N., Cheu, J. W., Yuen, V. W., Chiu, D. K., Goh, C., Lee, D. P. H., Zhang, M. S., Ng, I. O., & Wong, C. C. (2021) · Hepatology Communications · doi:10.1002/hep4.1682 · Cited by 40
Sprooten, J., Vankerckhoven, A., Vanmeerbeek, I., Borràs, D., Berckmans, Y., Wouters, R., Laureano, R. S., Baert, T., Boon, L., Landolfo, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003609 · Cited by 39
Kuang, X., Wang, Z., Luo, Z., He, Z., Liang, L., Gao, Q., Li, Y., Xia, K., Xie, Z., Chang, R., et al. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.02.050 · Cited by 38
Maiorano, B. A., Lorusso, D., Maiorano, M. F. P., Ciardiello, D., Parrella, P., Petracca, A., Cormio, G., & Maiello, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073871 · Cited by 42
“Even if a cut-off for TMB has not been established, it is considered a surrogate of neoantigen load, which is associated with a good response to ICIs [86,87].”
BackgroundLayer‐by‐layer interleukin‐12 nanoparticles drive a safe and effective response in ovarian tumors
Barberio, A. E., Smith, S. G., Pires, I. S., Iyer, S., Reinhardt, F., Melo, M. B., Suh, H., Weinberg, R. A., Irvine, D. J., & Hammond, P. T. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10453 · Cited by 42
“Ovarian cancer is one such malignancy that often presents as a “cold” tumor and has been particularly unresponsive to checkpoint inhibition.(8) One method to bring immunotherapy to such”
MethodNetwork approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
“However, the currently available biomarkers, often rely on tumor tissue samples, such as elevated tumor PD-L1 expression in the tumor microenvironment (TME) [246, 247], the tissue TMB (tTMB) [248, 249], and others, have been unable to accurately identify the subset of cancer patients who benefit from these therapies.”
BackgroundJie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 40
“demonstrated that a significant positive correlation could be observed between TMB and objective response rate (ORR) with ICIs in 27 tumor types (68).”
BackgroundBiomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Goodman, R. S., Jung, S., Balko, J. M., & Johnson, D. B. (2023) · Immunological Reviews · doi:10.1111/imr.13249 · Cited by 40
MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer
Wu, Y., Liu, Q., Xie, Y., Zhu, J., Zhang, S., Ge, Y., Guo, J., Luo, N., Huang, W., Xu, R., et al. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01207-0 · Cited by 39
“However, immuno-therapy is not effective enough for most ovarian cancer patients due to the suppressive immune microenvironment and the characteristics of “cold” tumors [5, 6].”
BackgroundSilva, H. J., Martin, G. A., Birocchi, F., Wehrli, M., Kann, M. C., Supper, V. M., Parker, A. L., Graham, C., Bratt, A., Bouffard, A. A., et al. (2024) · Blood · doi:10.1182/blood.2023023210 · Cited by 39
Calcium nanoparticles target and activate T cells to enhance anti-tumor function
Yang, W., Feng, Z., Lai, X., Li, J., Cao, Z., Jiang, F., Chen, F., Zhan, S., Kong, F., Yang, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54402-y · Cited by 45
Luo, C., Zhang, R., Guo, R., Wu, L., Xue, T., He, Y., Jin, Y., Zhao, Y., Zhang, Z., Zhang, P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.007 · Cited by 38
Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., Antonio Lopez-beltran, B., Liang Cheng, C., Battelli, N., Montironi, R., et al. (2019) · Cancers · doi:10.3390/cancers11060830 · Cited by 37
“Even if RCC may be related to high mutational burden, the impact of this factor on predictions of response to immune-checkpoint inhibitors has not yet been fully assessed [87].”
BackgroundKRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
Rosamaria, P., Petriella, D., Lacalamita, R., Montrone, M., Catino, A., Pizzutilo, P., Antonietta, B. M., Zito, A. F., Bene, G. D., Zonno, A., et al. (2019) · Cancers · doi:10.3390/cancers11081145 · Cited by 42
“Tumor mutational burden (TMB) is a potential biomarker, also in NSCLC, for response to immunotherapy targeting PD-1/PD-L1 [16,17].”
BackgroundInfluentialRemón, J., García‐Campelo, R., de Álava, E., Vera, R., Rodríguez‐Peralto, J. L., Rodríguez-Lescure, Á., Bellosillo, B., Garrido, P., Rojo, F., & Álvarez-Alegret, R. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02211-x · Cited by 37
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
Yang, Y., Yu, Y., & Lü, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1622-5 · Cited by 40
“national studies are applicable to the Chinese population (Yarchoan et al., 2017).”
BackgroundXie, F., Bai, Y., Yang, X., Long, J., Mao, J., Lin, J., Wang, D., Song, Y., Xun, Z., Huang, H., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107135 · Cited by 41
Zhang, N., Guoqing, W., Yu, X., Mi, Y., Xin, H., Li, X., & Wang, R. (2021) · BioMed Research International · doi:10.1155/2021/1780860 · Cited by 43
“TMB is defined as the total number of DNA mutations per megabases (Mb) [13].”
BackgroundFind the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
“As shown by Cristescu et al. [13], melanomas with TMB-H have a RR to pembrolizumab of 42% versus only 9% of melanomas with TMB-L.”
InfluentialZouein, J., Kesrouani, C., & Kourié, H. R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0336 · Cited by 42
Fanale, D., Corsini, L. R., Scalia, R., Brando, C., Cucinella, A., Madonia, G., Dimino, A., Filorizzo, C., Barraco, N., Bono, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103597 · Cited by 43
Tan, Q., Yin, S., Zhou, D., Chi, Y., Man, X., & Li, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.779786 · Cited by 46
“TMB refers to the total number of base substitutions, somatic gene coding errors, and gene deletion or insertion errors detected per million bases (103).”
BackgroundThe DNA damage induced immune response: Implications for cancer therapy
Barros, E. M., McIntosh, S., & Savage, K. I. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103409 · Cited by 40
Cheng, Y., Bu, D., Zhang, Q., Sun, R., Lyle, S. R., Zhao, G., Dong, L., Li, H., Zhao, Y. C., Yu, J., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.10.019 · Cited by 39
Matsushima, S., Ajiro, M., Iida, K., Chamoto, K., Honjo, T., & Hagiwara, M. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6056 · Cited by 42
“Meta-analyses for PD-1 blockade responses highlight the importance of neoantigens, derived from nonsynonymous mutations in cancer cells, for antitumor immune responses (8, 9).”
BackgroundResultInfluentialA Systematic Pan-Cancer Analysis of CASP3 as a Potential Target for Immunotherapy
Zhou, Z., Xu, S., Jiang, L., Tan, Z., & Wang, J. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.776808 · Cited by 36
“TMB is defined as the total number of somatic gene coding, base insertion, replacement, or deletion errors detected per million bases (Yarchoan et al., 2017), which is an important biological indicator of the extent of mutation in tumours; a higher TMB often indicates better outcomes for tumour immunotherapy (Le et al.”
BackgroundImmune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer
Hajj, J. E., Reddy, S., Verma, N., Huang, E. H., & Kazmi, S. M. A. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00927-2 · Cited by 40
“It correlates with response to immunotherapy across nearly all cancer types [80].”
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 39
Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer
Zhou, Q., Xu, J., Xu, Y., Sun, S., & Chen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176647 · Cited by 39
“Frontiers in Immunology 14 (PD-L1), as well as tumor mutational burden (TMB), are commonly used as indicators for the evaluation of the efficacy of immunotherapy and identify populations that are likely to benefit from immunotherapy (19).”
MethodDakal, T. C., George, N., Xu, C., Suravajhala, P., & Kumar, A. (2024) · Cancers · doi:10.3390/cancers16091626 · Cited by 46
“A pooled investigation of 27 tumor types found that anti-PD-1 treatments are the only immunotherapies that respond to high-TMB [128,129].”
BackgroundConsensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management
Mete, Ö., Boucher, A., Schrader, K. A., Abdel-Rahman, O. M., Bahig, H., Ho, C., Hasan, O. K., Lemieux, B., Winquist, E., Wong, R. P. W., et al. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09836-x · Cited by 41
Immunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 43
Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System
Xing, J., Ying, H., Ji, L., Gao, Y., Sun, Z., Li, J., Bai, C., Cheng, Y., & Wu, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00132 · Cited by 37
“74, was demonstrated in previous research (17).”
Patel, R. R., Ramkissoon, S. H., Ross, J. S., & Weintraub, L. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28338 · Cited by 38
“TMB was calculated as mutations per megabase and categorized as low (0-6), intermediate (6-20), or high (>20).”
MethodWang, Y., Xu, Y., Dai, X., Lin, X., Shan, Y., & Ye, J. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108069 · Cited by 36
Lamberti, G., Andrini, E., Sisi, M., Federico, A. D., & Ricciuti, B. (2020) · Future Oncology · doi:10.2217/fon-2020-0215 · Cited by 36
CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses
Lin, H., Lian, J., Xia, L., Guan, G., & You, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s271807 · Cited by 38
Zhang, N., Shi, J., Shi, X., Chen, W., & Liu, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s275688 · Cited by 41
Liao, Y., He, D., & Wen, F. (2021) · Immunogenetics · doi:10.1007/s00251-021-01223-8 · Cited by 39
“In addition, recent studies have found that the tumor mutation burden (TMB) can independently predict the efficacy of PD-1/PD-L1 inhibitors (Goodman et al. 2017; Yarchoan et al. 2017).”
BackgroundIdentification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
Verdon, D. J., & Jenkins, M. R. (2021) · Cancers · doi:10.3390/cancers13164245 · Cited by 42
Chen, K. Y., Popović, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., et al. (2022) · Cancers · doi:10.3390/cancers14215347 · Cited by 39
“Approximately half of the differences in the objective response rate across cancer types may be explained by the TMB, with higher TMBs correlating with higher benefit [15,16].”
BackgroundSelf-citationShinohara, S., Takahashi, Y., Komuro, H., Matsui, T., Sugita, Y., Demachi‐Okamura, A., Muraoka, D., Takahara, H., Nakada, T., Sakakura, N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003765 · Cited by 38
Exosomal PD-L1 in cancer and other fields: recent advances and perspectives
Lu, M., & Yang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1395332 · Cited by 45
“Various biological factors including lower tumor burdens, mutational burden, PD-L1 expression, and oncogenic virus integration are closely associated with a higher likelihood of response (34 – 39).”
BackgroundImmunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies
Alsina, M., Moehler, M. H., & Lorenzen, S. (2018) · Oncology Research and Treatment · doi:10.1159/000488120 · Cited by 36
Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we?
Evans, M., O’Sullivan, B., Smith, M. R., & Tanière, P. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.09 · Cited by 36
“Interestingly, there is evidence that the predictive power of TMB is limited not only to NSCLC; there is increasing evidence to suggest that TMB can meaningfully predict checkpoint inhibitor response across a range of solid malignancies (23,24).”
BackgroundKöster, J., & Plasterk, R. H. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-42729-2 · Cited by 35
Möck, A., Zschäbitz, S., Kirsten, R., Scheffler, M., Wolf, B., Herold‐Mende, C. C., Kramer, R., Busch, E., Jenzer, M., Jäger, D., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02428-3 · Cited by 35
Patrinely, J. R., Baker, L. X., Davis, E. J., Song, H., Ye, F., & Johnson, D. B. (2020) · Cancer · doi:10.1002/cncr.32984 · Cited by 36
“Immune checkpoint inhibitors induce durable clinical responses in variable percentages of the 17 different cancer types for which they are approved, and nearly one-half of all patients with cancer now are eligible for these therapies.(1,2) Treatment with antibodies to programmed cell death protein 1 and its ligand (an…”
BackgroundEvaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
Wessely, A., Heppt, M. V., Kammerbauer, C., Steeb, T., Kirchner, T., Flaig, M. J., French, L. E., Berking, C., Schmoeckel, E., & Reinholz, M. (2020) · Cancers · doi:10.3390/cancers12092516 · Cited by 37
“ICB has achieved the best results in cancer entities with a high tumor mutational burden, as these tumors are more likely to express neoantigens that can be recognized as foreign by immune cells [26].”
BackgroundMetastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
Roberto, M., Botticelli, A., Panebianco, M., Aschelter, A. M., Gelibter, A. J., Ciccarese, C., Minelli, M., Nuti, M., Santini, D., Laghi, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657639 · Cited by 39
“Tumor Mutational Burden TMB is defined as the total number of mutations per coding area of the tumor genome, measured as mutations per megabase (mutations/Mb) (81).”
BackgroundRamos‐Paradas, J., Hernández-Prieto, S., Lora, D., Sanchez, E., Rosado, A., Caniego-Casas, T., Carrizo, N., Enguita, A. B., Muñoz-Jimenez, M. T., Rodriguez, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001904 · Cited by 38
“…tumor mutational burden (TMB), defined as the total number of mutations per megabase of the tumor genome encoding area, has been identified as a promising predictive tool in many solid tumors, 13–15 including melanoma 16 and NSCLC, 17 18 which present the highest prevalence of somatic mutations.”
BackgroundZhao, P., Xu, Y., Ji, W., Li, L., Qiu, L., Zhou, S., Qian, Z., & Zhang, H. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s346044 · Cited by 35
“death-1 (αPD-1) and anti-programmed cell death ligand-1 (αPD-L1) antibodies have shown significant antitumor activity in a variety of tumor types.(3,4) However,”
BackgroundFacts and Hopes for Immunotherapy in Renal Cell Carcinoma
Yao, C., Zhang, T., Wu, T., & Brugarolas, J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2372 · Cited by 37
Wang, H., Arulraj, T., Kimko, H. H. C., & Popel, A. S. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00405-9 · Cited by 37
“In addition, the number of NSCLC-speci fi c T cell clones was found to be correlated with tumor mutational burden 47 , which is a known predictive biomarker for immune checkpoint inhibition in NSCLC 48 .”
Genome-guided discovery of cancer therapeutic targets
Konda, P., Garinet, S., Allen, E. M. V., & Viswanathan, S. R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112978 · Cited by 36
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
Deep learning in digital pathology for personalized treatment plans of cancer patients
Wen, Z., Wang, S., Yang, D. M., Xie, Y., Chen, M., Bishop, J., & Xiao, G. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.02.003 · Cited by 34
Immune Resistance Mechanisms and the Road to Personalized Immunotherapy
Piper, M., Kluger, H. M., Ruppin, E., & Hu‐Lieskovan, S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390290 · Cited by 43
Li, J., Liu, H., Liu, W., Zong, P., Huang, K., Li, Z., Li, H., Xiong, T., Tian, G., Li, C., et al. (2023) · Briefings in Functional Genomics · doi:10.1093/bfgp/elad032 · Cited by 37
Chen, D., Zhang, R., Huang, X., Ji, C., Xia, W., Qi, Y., Yang, X., Lin, L., Wang, J., Cheng, H., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00560-6 · Cited by 35
“Several biomarkers associated with immunological status have been discovered with variable success, including tumor mutation burden (TMB) [4], specific genetic mutations [5], expression level of PD-L1 [6] and presence of tumor immune infiltrates [7].”
BackgroundJin, Y., Wu, Y., Reuben, A., Zhu, L., Gay, C. M., Wu, Q., Zhou, X., Mo, H., Zheng, Q., Ren, J., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00703-x · Cited by 38
“However, the clinical bene fi t from ICI is limited for SCLC patients compared with other cancer types 5 despite that most SCLC patients are smokers and that the tumors usually have high tumor mutational burden (TMB), both of which have been reported to be associated with clinical bene fi t for ICI…”
Zhang, J., Choi, H., Kim, Y., Park, J., Cho, S., Kim, E., Cho, A., Lee, J. Y., Choi, J., Low, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011346 · Cited by 39
Acquired resistance to immunotherapy in MMR-D pancreatic cancer
Hu, Z. I., Hellmann, M. D., Wolchok, J. D., Vyas, M., Shia, J., Stadler, Z. K., Diaz, L. A., & O'Reilly, E. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0448-1 · Cited by 34
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 35
Supramolecular Self-Assembled Nanostructures for Cancer Immunotherapy
Huang, Z., Song, W., & Chen, X. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00380 · Cited by 35
“One key problem is the low response rate—the overall response rate of immune checkpoint therapy in the majority of cancer types is lower than 20% (Yarchoan et al., 2017; Sanmamed and Chen, 2018), while CAR-T therapy is only effective in blood cancer (Martinez and Moon, 2019).”
BackgroundAkahane, T., Kitazono, I., Yanazume, S., Kamio, M., Togami, S., Sakamoto, I., Nohara, S., Yokoyama, S., Kobayashi, H., Hiraki, T., et al. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00753-6 · Cited by 34
Medjebar, S., Truntzer, C., Perrichet, A., Limagne, E., Fumet, J.-D., Richard, C., Elkrief, A., Routy, B., Rébé, C., & Ghiringhelli, F. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1836766 · Cited by 39
Gokuldass, A., Draghi, A., Papp, K., Borch, T. H., Nielsen, M., Westergaard, M. C. W., Andersen, R. S., Schina, A., Bol, K. F., Chamberlain, C. A., et al. (2020) · Cancers · doi:10.3390/cancers12113344 · Cited by 35
“Although it is generally accepted that tumor types with a higher average TMB respond more frequently to immunotherapy [33,34], the value of TMB for predicting clinical outcome following immunotherapy within tumor types or subtypes is debated and several studies have failed to link TMB to immunological quantitative bio…”
BackgroundEvolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice
Moaven, O., Mangieri, C. W., Stauffer, J. A., Anastasiadis, P. Z., & Borad, M. J. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00395 · Cited by 37
“ICIs have had a profound impact on the management of malignant melanoma, where response rates are approximately 35% and translated into unprecedented clinical outcomes.(71) Unfortunately, the majority of other malignancies currently have very low response rates to ICIs via primary, adaptive, or acquired resistance mec…”
BackgroundFavorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9
Kinny‐Köster, B., Habib, J. R., Wolfgang, C. L., He, J. P., & Javed, A. A. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-426 · Cited by 35
“Except in patients with a high mutational burden, some long-term survivors have benefitted from specifically developed neoantigens as T-cell targets (21-23).”
BackgroundHirama, T., Tokita, S., Nakatsugawa, M., Murata, K., Nannya, Y., Matsuo, K., Inoko, H., Hirohashi, Y., Hashimoto, S., Ogawa, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146356 · Cited by 37
“Since dMMR-CRCs and other solid cancers are sensitive to immune checkpoint inhibitors (ICI), dMMR or MSI-H was approved by the FDA as the first tissue-agnostic bio-marker across cancer types (3–5).”
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
He, Y., Lu, M., Che, J., Chu, Q., Zhang, P., & Chen, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716844 · Cited by 37
Chen, X., Lu, Y., Yu, H., Du, K., Zhang, Y., Yang, N., & Huang, Q. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1982494 · Cited by 37
An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
Mollica, V., Marchetti, A., Rosellini, M., Nuvola, G., Rizzo, A., Santoni, M., Cimadamore, A., Montironi, R., & Massari, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413519 · Cited by 38
“Defects in MMR proteins and the subsequent MSI-H state led to the collection of mutational loads in cancer-related genes along with several neoantigens’ synthesis, thus enhancing the anti-tumor immune response of the host [40,41].”
BackgroundBiomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Neoantigens as potential vaccines in hepatocellular carcinoma
Repáraz, D., Ruiz, M., Llópiz, D., Silva, L., Vercher, E., Aparicio, B., Egea, J., Tamayo, I., Hervás‐Stubbs, S., García-Balduz, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003978 · Cited by 36
“16 As opposed to heavily mutated tumors, like melanoma or lung cancer, HCC is a tumor with a low/ intermediate TMB (five mutations/Mbase).”
Precision Combination Therapies Based on Recurrent Oncogenic Coalterations
Li, X., Kong, E., Yan, G., Dereli, Z., Bozorgui, B., Imanirad, P., Elnaggar, J. H., Luna, A., Menter, D. G., Pilie, P. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0832 · Cited by 36
Zhang, S., Feng, Y., Meng, M., Li, Z., Li, H., Lin, L., Xu, C., Chen, J., Hao, K., Tang, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121794 · Cited by 36
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.